Bio-IT World: Venture, Innovation & Partnering
Uniting Investors and Leaders: Advancing Innovation
April 17, 2024 ALL TIMES EST
Wednesday, April 17
Registration Open
Morning Coffee: Meet and Greet
Unveiling the Future: Strategic Investment Opportunities in Biotech & Drug Discovery
Scott Penberthy, Chief Technology Officer, Google Cloud
Join Scott Penberthy, CTO of Google, as he unveils groundbreaking insights for investors in biotechnology and drug discovery. Penberthy will set the tone and theme of the day by exploring investment trends in these dynamic fields. With a visionary discussion on the transformative power of AI-driven initiatives in healthcare, attendees will gain valuable perspectives on how technologies like AI, next-generation sequencing, and cloud computing are reshaping drug development.
Unlocking the Future: Emerging Investment Trends in Bio-IT
Rana Lonnen, Managing Director, Novartis
In recent years, Bio-IT investment has surged, attracting diverse stakeholders. Explore the spectrum of investors, from venture capitalists to institutional funds. Discover the pivotal role of pharmaceutical companies and the technologies commanding investment interest, from AI-driven drug discovery to quantum computing innovations. Dive into the evolving landscape where opportunity meets innovation at the forefront of biotech advancement.
Brett B. Cook, Partner, F-Prime Capital
Cris De Luca, Partner, Sanofi Ventures
Luba Greenwod, Managing Partner, Binney Street Capital, Dana-Farber Cancer Institute
Sofia Guerra, Vice President, Bessemer Venture Partners
Stephanie Oestreich, Managing Director, Myeloma Investment Fund of the MMRF
Strategies for Biotech Success: Insights on Raising Capital from CEOs and VCs
Rahul Chaturvedi, Founder & CEO, Clora, Inc.
This presentation offers invaluable perspectives on raising capital in the dynamic biotech landscape. Delve into recent shifts in capital acquisition, anticipate market expectations into late 2024/early 2025, and gain insights on selecting the right investor amidst competitive markets. Navigate R&D expectations and explore strategies for differentiation while effectively managing execution and board dynamics. Triangulate decisions for sustainable growth and success in the biotech sector.
Kimberly Nearing, Venture Partner, Investment, BVCF Management Ltd.
Trevor Perry, Partner, Selas Ventures
Jami Rubin, CFO, Boundless Bio; Venture Partner, ARCH Venture Partners
Chris Shibutani, MD, MBA, Global Investment Research, Goldman Sachs
Scott T. Megaffin, CEO, Adiso Therapeutics
Networking Coffee Break
Accelerating Drug Development: Harnessing AI as a Problem-Solving Tool
Zach Taft, Co-Founder, Clinical Research Innovation Consortium (CRIC), Memorial Sloan Kettering Cancer Center
Explore the latest in AI/ML investments transforming drug discovery. Case studies showcase AI's role in drug development. From research to clinical, AI enhances efficiency. Cutting-edge advances like LLMs revolutionize drug discovery. Remember, AI's value lies in delivering better drugs, not just algorithms. Prioritize rigorous clinical validation for investor and patient confidence. Join us to invest in a future where AI serves patients and drives real impact.
Molly Gibson, Origination Partner, Flagship Pioneering
John J. Keilty, Venture Partner, Third Rock Ventures
Dave Latshaw II, PhD, MBA, CEO and Co-Founder, BioPhy
Imogen Pryce, PhD, COO, R&D, Relay Therapeutics Inc
Empowering Innovation: Build vs. Buy in Data Science and Engineering
Mika Newton, CEO, xCures
Join a critical discussion on biotech investment strategies, emphasizing data science's role in startup success and larger pharma decisions. Explore the balance between in-house expertise and external partnerships, outsourcing implications, and the valuation of technology assets in biotech/pharma. Essential for investors targeting sustainable growth.
Dana Callow, Founder & Managing Partner, Boston Millennia Partners
Thomas Neyarapally, CEO & Co-Founder, Archetype Therapeutics, Inc.
Miruna Sasu, President and CEO, COTA, Inc.
Christina Vorvis, Director, AbbVie Ventures
Xiaoying Wu, MD, MS, Vice President, Data Science & Digital Health, Janssen Pharmaceuticals, Inc.
Networking Lunch
Enjoy a delightful networking lunch to discuss trends, share ideas, and savor a delectable meal together.
Discover Arena BioWorks
Lisa Hughes, News Anchor, WBZ-TV News, CBS, Boston
Steve Pagliuca, Chairman, CEO and Founder, PagsGroup
Discover Arena BioWorks, a privately funded biomedical institute committed to revolutionizing healthcare solutions. Steve Pagliuca, co-founder and Executive Chair of Arena, leverages his vast experience in private equity and biotech investment to accelerate innovation with independence. Pagliuca's strategic prowess ensures optimal asset allocation and company exits, fostering a vision for groundbreaking biomedical research and therapeutics. Join us for insights into their journey at our investment-focused fireside chat.
Radical Candor on Investment and Innovation
Magnus Björsne, PhD, MBA, CEO, AstraZeneca BioVentureHub
Mats Sundgren, PhD, Senior Industry Scientific Director, i-HD (European Institute for Innovation through Health Data)
A discussion with Magnus Björsne, PhD, MBA, who holds the position of CEO at AstraZeneca BioVentureHub. This groundbreaking program fosters open innovation by providing smaller biotech firms and academic organizations with access to the extensive skills and capabilities housed within a major pharmaceutical company.
Nurturing Innovation & Investment in Early-Stage Biotech and Bio-IT
Mats Sundgren, PhD, Senior Industry Scientific Director, i-HD (European Institute for Innovation through Health Data)
Amidst the burgeoning landscape of life science and healthcare innovation, a panel discussion explores the pivotal role of incubators in nurturing start-ups. Health data and AI technologies, alongside expertise-sharing, foster unprecedented opportunities. Insights from pharma, vendors, and investors emphasize criteria for start-up selection, highlighting early access and impact investing. Incubators—led effectively—drive innovation, bridge research-to-patient gap, and generate revenue, creating a mutually beneficial scenario in the healthcare ecosystem.
Yair Benita, PhD, CTO, AION Labs
Isaac Bentwich, MD, Founder & CEO, Quris Technologies Ltd.
Magnus Björsne, PhD, MBA, CEO, AstraZeneca BioVentureHub
Daniel Franke, Investment Director, Technology Investments, M Ventures
Michael R. Schlabach, PhD, Senior Vice President, CSO, Partner Team, Curie.Bio
Networking Refreshment Break
How to Sustain Massachusetts as a Bio-Tech Hub and Investment Powerhouse?
William T. Mayo, Senior Vice President, Research, IT, Bristol Myers Squibb
Explore the nuances of sustaining biotech investment prowess in a concise panel discussion tailored for investors. Delve into the advantages and drawbacks of investing in a hub, with a focus on the pivotal role of ARPA-H Boston. Examine biotech sustainability through talent attraction and retention, as demonstrated by the launches of Portal Innovation and Biomedical Institute. Highlight the vital contributions of large pharmaceutical companies and hospitals in Boston and Cambridge. Gain insights from key stakeholders in the Massachusetts biotech ecosystem, evaluate the necessity of biotech hubs, and uncover strategies for scaling beyond Boston and Cambridge while addressing potential threats to industry dominance.
Joe Collura, Director, Portal Innovations, LLC
Jason Cordeiro, Chief Operating & Innovation Officer, Massachusetts Biotechnology Council
Yvonne Hao, Secretary of Economic Development, Commonwealth of Massachusetts
Erin McKenna, Operating Partner, Amplify, Mass General Brigham Innovation
Joe Shonkwiler, MD, MBA, MPP, COO, ARPA-H
Close of Bio-IT World: Venture, Innovation & Partnering Conference